Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Hao Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6282-0237; OpenAlex author ID A5100353573. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 10

  1. Immune-Mitochondrial Crosstalk in Pancreatic Adenocarcinoma: Systematic Identification of Prognostic Biomarkers Through Immune Dictionary Framework Last author DOI 10.2174/0118715303422686250925054821↗
  2. Decipher the single-cell level responses to chemotherapy in pancreatic ductal adenocarcinoma by a cross-time context graph model. Co-author DOI 10.1016/j.canlet.2025.217751↗
  3. A retrospective cohort study on the differential overall survival rates between surgical intervention and chemotherapy in stage IV pancreatic cancer patients. Co-author DOI 10.21037/gs-2025-269↗
  4. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study. Co-author DOI 10.1097/js9.0000000000000264↗
  5. Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation. Co-author DOI 10.1016/j.jep.2021.114691↗
  6. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. Co-author DOI 10.1186/s12863-021-01019-5↗
  7. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Co-author DOI 10.1016/j.canlet.2020.06.011↗
  8. Feasibility of multimodal multiphoton microscopy to facilitate surgical margin assessment in pancreatic cancer. Co-author DOI 10.1364/ao.391315↗
  9. Serum tRNA-derived small RNAs as potential novel diagnostic biomarkers for Pancreatic Ductal Adenocarcinoma Last author DOI 10.21203/rs.3.rs-63978/v1↗
  10. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Co-author DOI 10.1016/j.canlet.2013.03.001↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shutong Shao · 1 shared paper, 2025 · strength 0.37
  2. Bole Tian · 1 shared paper, 2025 · strength 0.37
  3. Jiangang Zhao · 1 shared paper, 2026 · strength 0.36
  4. Xinghe Liao · 1 shared paper, 2026 · strength 0.36
  5. Ping Li · 1 shared paper, 2026 · strength 0.36
  6. Fenglin Zhang · 1 shared paper, 2026 · strength 0.36
  7. Zhen Chen · 2 shared papers, 2022 · strength 0.35
  8. Panling Xu · 2 shared papers, 2022 · strength 0.35
  9. Gang Yang · 2 shared papers, 2020–2025 · strength 0.34
  10. Taiping Zhang · 2 shared papers, 2020–2025 · strength 0.34
  11. Lei You · 2 shared papers, 2020–2025 · strength 0.34
  12. Chenghong Peng · 2 shared papers, 2020–2023 · strength 0.24
  13. Xiaxing Deng · 2 shared papers, 2020–2023 · strength 0.24
  14. Jinxin Tao · 1 shared paper, 2025 · strength 0.21
  15. Jiangdong Qiu · 1 shared paper, 2025 · strength 0.21
  16. Bo Xu Ren · 1 shared paper, 2025 · strength 0.21
  17. Xinqi Li · 1 shared paper, 2025 · strength 0.21
  18. Guangyu Chen · 1 shared paper, 2025 · strength 0.21
  19. Jin Gu · 1 shared paper, 2025 · strength 0.21
  20. Yu-Pei Zhao · 1 shared paper, 2025 · strength 0.21
  21. Ping Li · 1 shared paper, 2022 · strength 0.19
  22. Juying Jiao · 1 shared paper, 2022 · strength 0.19
  23. Chien‐shan Cheng · 1 shared paper, 2022 · strength 0.19
  24. Huifeng Gao · 1 shared paper, 2022 · strength 0.16
  25. Yujie Li · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.